This article has a correction

Please see: Ann Rheum Dis 2008;67:1200

Ann Rheum Dis 67:614-619 doi:10.1136/ard.2007.075523
  • Extended report

Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study

  1. L Sailler1,
  2. C Pereira1,
  3. A Bagheri1,
  4. M Lapeyre-Mestre1,
  5. J L Montastruc1,
  6. P Arlet2,
  7. E Arlet-Suau2,
  8. E Uro-Coste3,
  9. H Roussel4,
  10. D Adoue5,
  11. B Fournie6,
  12. L Zabraniecki6,
  13. M Laroche7,
  14. P Cintas8
  1. 1
    University of Tolouse, Toulouse, France
  2. 2
    Internal Medicine Department, Salles Le Tallec-Tapie, Pavillon Dieulafoy, CHU Purpan, Toulouse, France
  3. 3
    Pathology Department, CHU Rangueil, Toulouse, France
  4. 4
    Direction Régionale du Service Médical, CNAMTS, Toulouse, France
  5. 5
    Internal Medicine Department, Pavillon des Médecines, CHU Purpan, Toulouse, France
  6. 6
    Rheumatology Department, CHU Purpan, Toulouse, France
  7. 7
    Rheumatology Department, CHU Rangueil, Toulouse, France
  8. 8
    Neurology Department, CHU Rangueil, Toulouse, France
  1. Dr L Sailler, Unit of Pharmacoepidemiology, EA 3696, Clinical Pharmacology Department, Paul Sabatier University, 37 Allées Jules Guesdes, 31000 Toulouse, France; sailler.l{at}
  • Accepted 26 August 2007
  • Published Online First 3 September 2007


Objective: Case reports have suggested that lipid-lowering drugs (LLDs), especially statins, could induce or reveal chronic muscle diseases. We conducted a study to evaluate the association between chronic muscle diseases and prior exposure to LLDs.

Method: This was a retrospective study of chronic primary muscle disease cases newly diagnosed at the Toulouse University Hospitals between January 2003 and December 2004 among patients living in the Midi-Pyrénées area, France. All patients remained symptomatic for more than 1 year after drug withdrawal, or required drugs for inflammatory myopathy. Data on the patient’s exposure to LLDs and to other drugs were compared with that of matched controls (5/1) selected through the Midi-Pyrénées Health Insurance System database.

Results: A total of 37 patients were included in the study. Of those, 21 (56.8%) suffered from dermatomyositis (DM) or polymyositis (PM), 12 (32.4%) from genetic myopathy, and 4 (10.8%) from an unclassified disease. The prevalence of exposure to statins was 40.5% in patients and 20% in controls (odds ratio (OR) 2.73, 95% confidence interval (CI) 1.21–6.14; p<0.01). There was a significant positive interaction between statins and proton pump inhibitors exposure (weighted OR 3.3, 95% CI 1.37–7.54; p = 0.02). Statin exposure rate was 47.6% among patients with DM/PM (OR 3.86, 95% CI 1.30–11.57; p<0.01). There was no difference between patients and controls for exposure to fibrates.

Conclusion: Patients who developed chronic muscle diseases after the age of 50, including DM/PM, had a higher than expected frequency of prior exposure to statins. Further studies are needed to confirm this association and the role of proton pump inhibitors.


  • Competing interests: None.